Biblio Discovery — Demo Discovery Service

55 results for "Kenneth C. Anderson"

Showing 1–20 · 0.22 seconds · RSS

  1. Journal Article

    Multiple myeloma: the (r)evolution of current therapy and a glance into future

    Annamaria Gulla; Kenneth C. Anderson

    Haematologica, Vol. 105 No. 10 · 2020 · English · DOAJ Scopus

    Over the past 20 years, the regulatory approval of several novel agents to treat multiple myeloma (MM) has prolonged median patient survival from 3 to 8-10 years. Increased understanding of MM biology has translated to advances in diagnosis, prognosis, and response assessment, as well as informed…

  2. Journal Article

    New Frontiers in the Treatment of Multiple Myeloma

    Janice Jin Hwang; Irene M. Ghobrial; Kenneth C. Anderson

    The Scientific World Journal, Vol. 6 · 2006 · English · DOAJ Scopus

    Recent leaps in elucidating the biology of myeloma, particularly the intracellular pathways and the complex interaction with the bone marrow microenvironment, have resulted in an unprecedented surge of novel, targeted therapies and therapeutic regimens. There are currently over 30 new agents being…

  3. Journal Article

    Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

    Shih-Feng Cho; Kenneth C. Anderson; Yu-Tzu Tai

    Frontiers in Immunology, Vol. 9 · 2018 · English · DOAJ Scopus

    The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma (RRMM) was a critical advance for immunotherapies for multiple myeloma (MM). Importantly, the outcome of patients continues to…

  4. Journal Article

    Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today’s treat-to-target era

    Li Zhang; Yu-Tzu Tai; Matthew Zhi Guang Ho et al.

    Experimental Hematology & Oncology, Vol. 6 No. 1 · 2017 · English · DOAJ Scopus

    Abstract B cell lymphoma and multiple myeloma (MM) are the most common hematological malignancies which benefit from therapeutic monoclonal antibodies (mAbs)-based immunotherapies. Despite significant improvement on patient outcome following the use of novel therapies for the past decades, curative…

  5. Journal Article

    Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1

    Yu-Tzu Tai; Shih-Feng Cho; Kenneth C. Anderson

    Frontiers in Immunology, Vol. 9 · 2018 · English · DOAJ Scopus

    Immunomodulatory drugs and monoclonal antibody-based immunotherapies have significantly improved the prognosis of the patients with multiple myeloma (MM) in the recent years. These new classes of reagents target malignant plasma cells (PCs) and further modulate the immune microenvironment, which…

  6. Journal Article

    Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myeloma

    Arghya Ray; Yan Song; Ting Du et al.

    Blood Cancer Journal, Vol. 12 No. 4 · 2022 · English · DOAJ Scopus

    Abstract Interaction of plasmacytoid dendritic cells (pDCs) with multiple myeloma (MM) cells, T- or NK-effector cells in the bone marrow (BM) microenvironment induces tumor cell growth, as well as inhibits innate and adaptive immune responses. Defining pDC-MM interaction-triggered immunosuppressive…

  7. Journal Article Full text

    Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma

    Shih-Feng Cho; Liang Lin; Lijie Xing et al.

    Antibodies, Vol. 6 No. 4 · 2017 · English · DOAJ Scopus

    2015 was a groundbreaking year for the multiple myeloma community partly due to the breakthrough approval of the first two monoclonal antibodies in the treatment for patients with relapsed and refractory disease. Despite early disappointments, monoclonal antibodies targeting CD38 (daratumumab) and…

  8. Journal Article

    BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma

    Debasmita Dutta; Jiye Liu; Kenneth Wen et al.

    Blood Cancer Journal, Vol. 13 No. 1 · 2023 · English · DOAJ Scopus

    Abstract Bortezomib (BTZ) is a standard-of-care treatment in multiple myeloma (MM); however, adverse side effects and development of resistance limit its long term benefit. To improve target specificity, therapeutic efficacy, and overcome resistance, we designed nanoparticles that encapsulate BTZ…

  9. Journal Article

    Bispecific antibodies in multiple myeloma treatment: A journey in progress

    Shih-Feng Cho; Tsung-Jang Yeh; Kenneth C. Anderson et al.

    Frontiers in Oncology, Vol. 12 · 2022 · English · DOAJ Scopus

    The incorporation of novel agents and monoclonal antibody-based therapies into the treatment of multiple myeloma (MM) has significantly improved long-term patient survival. However, the disease is still largely incurable, with high-risk patients suffering shorter survival times, partly due to…

  10. Journal Article

    Meaningful changes in end-of-life care among patients with myeloma

    Oreofe O. Odejide; Ling Li; Angel M. Cronin et al.

    Haematologica, Vol. 103 No. 8 · 2018 · English · DOAJ Scopus

    Patients with advanced myeloma experience a high symptom burden particularly near the end of life, making timely hospice use crucial. Little is known about the quality and determinants of end-of-life care for this population, including whether potential increases in hospice use are also accompanied…

  11. Journal Article

    CyTOF profiling of bone marrow immune dynamics across myeloma stages

    Dana Cholujova; Gabor Beke; Lubos Klucar et al.

    OncoImmunology, Vol. 14 No. 1 · 2025 · English · DOAJ Scopus

    Multiple myeloma (MM) orchestrates a profound disruption of immune balance within the bone marrow (BM) microenvironment, driving disease progression and therapeutic resistance. To better understand these complex immune dynamics, we used high-dimensional mass cytometry (CyTOF) profiling to…

  12. Journal Article

    Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma

    Jana Jakubikova; Danka Cholujova; Gabor Beke et al.

    JCI Insight, Vol. 8 No. 3 · 2023 · English · DOAJ Scopus

    To better characterize the heterogeneity of multiple myeloma (MM), we profiled plasma cells (PCs) and their B cell lymphopoiesis in the BM samples from patients with monoclonal gammopathy of undetermined significance, smoldering MM, and active MM by mass cytometry (CyTOF) analysis. Characterization…

  13. Journal Article

    Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment

    Claudio Cerchione; Saad Z. Usmani; A. Keith Stewart et al.

    Frontiers in Oncology, Vol. 12 · 2022 · English · DOAJ Scopus

    Multiple myeloma is a blood cancer characterized by clonal proliferation of plasma cells in the bone marrow. In recent years, several new drugs have been added to the therapeutic landscape of multiple myeloma, which have contributed to increased survival rates. However, while the use of…

  14. Journal Article Full text

    Microenvironmental Influence on Pre-Clinical Activity of Polo-Like Kinase Inhibition in Multiple Myeloma: Implications for Clinical Translation

    Douglas W. McMillin; Jake Delmore; Joseph Negri et al.

    PLoS ONE, Vol. 6 No. 7 · 2011 · English · PLOS Scopus

    Polo-like kinases (PLKs) play an important role in cell cycle progression, checkpoint control and mitosis. The high mitotic index and chromosomal instability of advanced cancers suggest that PLK inhibitors may be an attractive therapeutic option for presently incurable advanced neoplasias with…

  15. Journal Article

    RVd and CyBorD therapies remodel B-cell maturation signaling and alter immune and clonal architecture in multiple myeloma

    Zuzana Valuskova; Dana Cholujova; Gabor Beke et al.

    Cancer Biology & Therapy, Vol. 26 No. 1 · 2025 · English · DOAJ Scopus

    Background Multiple myeloma (MM) features plasma cell (PC) heterogeneity and alterations in B-cell differentiation and immune regulation. Although lenalidomide/bortezomib/dexamethasone (RVd) and cyclophosphamide/bortezomib/dexamethasone (CyBorD) are clinically effective, their precise impacts on…